Latanoprost Farmalider (Latanoprost)

Latanoprost is indicated for conditions that require reduction of intra‑ocular pressure, primarily within the glaucoma disease spectrum.

• Primary open‑angle glaucoma: lowers intra‑ocular pressure to slow visual field loss.
• Ocular hypertension: reduces elevated eye pressure to prevent progression to glaucoma.
• Secondary open‑angle glaucoma: helps control pressure when caused by other ocular conditions.
• Pseudoexfoliative glaucoma: decreases intra‑ocular pressure associated with exfoliative material deposition.
• Angle‑closure glaucoma post‑laser iridotomy: adjunctive pressure reduction.

• Latanoprost is a synthetic analogue of prostaglandin F₂α that binds to FP receptors on the ciliary body epithelium. Activation of these G‑protein‑coupled receptors increases remodeling of the extracellular matrix, enhancing uveoscleral outflow of aqueous humor. The resulting increase in outflow lowers intra‑ocular pressure, providing therapeutic benefit in glaucoma and ocular hypertension. The effect is sustained for 24 hours after a single drop, allowing once‑daily dosing.

Latanoprost may cause ocular and peri‑ocular adverse reactions, most of which are mild and reversible.

Common Side Effects

• Eye redness: transient hyperemia of the conjunctiva.
• Increased eyelash growth: longer, thicker lashes may appear.
• Iris pigmentation change: gradual darkening of eye color.
• Eye irritation: burning or stinging sensation after instillation.
• Blurred vision: temporary visual disturbance.
• Foreign body sensation: feeling of grit in the eye.

Serious or Rare Side Effects

• Severe eye inflammation: uveitis or iritis requiring medical attention.
• Allergic reaction: swelling, itching, or rash around the eye.
• Macular edema: fluid accumulation in the retina that can affect vision.
• Sudden loss of vision: rare but urgent ophthalmic emergency.
• Periorbital fat atrophy: loss of orbital fat leading to a sunken appearance.

When using Latanoprost, clinicians should observe specific safety measures to minimize risks and ensure optimal therapeutic outcomes.

• Monitor intra‑ocular pressure: schedule regular IOP measurements to assess efficacy.
• Assess for ocular infections: avoid initiating therapy in the presence of active conjunctivitis or keratitis.
• Caution in corneal disorders: patients with corneal dystrophies may experience increased irritation.
• Avoid concurrent prostaglandin analogs: additive pressure‑lowering effect can cause over‑reduction.
• Pregnancy and lactation: safety not established; weigh potential benefits against unknown risks.
• Store at room temperature: keep the bottle in its original packaging, protect from light and moisture.

Latanoprost can interact with other ophthalmic agents, potentially altering its efficacy or increasing adverse effects.

Major Interactions (Avoid)

• Other prostaglandin analog eye drops: combined use may cause excessive IOP reduction.
• Preservative‑containing anesthetics: may increase ocular surface irritation.
• Systemic carbonic anhydrase inhibitors: can diminish the IOP‑lowering effect of Latanoprost.

Moderate Interactions (Monitor Closely)

• Beta‑blocker eye drops: monitor IOP for additive pressure‑lowering effect.
• Topical corticosteroids: may counteract Latanoprost’s efficacy, requiring IOP checks.
• Anticholinergic ophthalmic agents: observe for changes in IOP response.